Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Gibson Dunn says it advised Velaris on its sale to Alaunos and a private placement
Gibson Dunn said it advised Velaris Therapeutics on its sale to Alaunos Therapeutics and a concurrent private placement. The firm said the financing was expected to support the combined company’s operations into 2029 and identified the transaction as work by its corporate team.
Key points
- Gibson Dunn described Velaris as a privately held biotechnology company.Gibson Dunn
- The firm said Velaris develops therapies for pulmonary arterial hypertension and related cardiopulmonary diseases.Gibson Dunn
- Gibson Dunn said partners Ryan Murr, Branden Berns and Melanie Neary worked on the transaction.Gibson Dunn
- The firm said of counsel Evan Shepherd also served on its team.Gibson Dunn